Big Pharma Still Hot for mAbs
Autoimmune, CNS Diseases: Top-Dollar Antibodies Deals
By Jennifer Boggs
Friday, November 11, 2011
Anyone who has followed the biopharma sector over the past decade knows that big pharma's lust for monoclonal antibody technology isn't going away any time soon. But a recent report and webinar by Deloitte Recap LLC, which broke down more than 1,000 deals over the last 10 years, showed some unexpected trends for companies working in the antibody space.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.